Efficacy and pharmacokinetics of XXXX in paediatric infections.

@entity1 @entity9102 @entity72277 @entity55 @entity798 @entity281 @entity4967 @entity1778 @entity2885 @entity526
Twenty-four @entity1 , ten of whom had an @entity281 due to @entity4967 -resistant, @entity9102 -sensitive bacteria, were treated with @entity9102 . A full clinical success was obtained in sixteen cases (13 @entity2885 , nine of them due to @entity4967 -resistant, @entity9102 -sensitive @entity526 , two @entity281 and one @entity55 ). Four @entity1 were improved (1 bronchiectasis, 3 @entity1778 ), three were unassessable and one failure occurred with a staphylococcal urinary tract @entity281 . A pharmacokinetic study was performed in three newborns (under three months) and ten @entity1 (mean age 3 years). @entity9102 was administered as four daily 30-min iv infusions. The mean dosage used in @entity1 under three months was 225 mg/kg/d @entity4967 and 9 mg/kg/d @entity798 . In @entity1 older than three months of age the mean dosage was 250 mg/kg/d @entity4967 and 16 mg/kg/d @entity798 . The pharmacokinetic results demonstrated similar serum concentrations of @entity4967 to those in earlier studies, and serum concentrations of @entity798 of 3.1 +/- 0.63 mg/l and 2.18 +/- 0.17 mg/ @entity72277 h respectively after infusion in newborns. For @entity1 , at the same times, the serum levels were respectively 2.3 +/- 0.9 mg/l and 1.4 +/- 0.9 mg/l. The peak serum concentrations of @entity798 were the same in the two groups of dosages (4.7 mg/l), but the half-lives of @entity798 were 1.1 h in @entity1 older than three months and 1.8 h in @entity1 younger than 3 months. The tolerance was good. @entity9102 may be useful as a first line antibiotic in infections in hospitalized @entity1 in the dosage described, as three or four injections daily, according to the age and the severity of the disease.
